OQROGet OQRO Pro
Politician trade (House)

NeoGenomics Laboratories, Inc. (NEO)Rep. Gilbert Cisneros (CA31) disclosed a purchase $1K–$15K

Rep. Gilbert Cisneros (CA31) disclosed a purchase of NeoGenomics Laboratories, Inc. in the $1K–$15K range.

$1,001–$15,000
Reported range · official band, not an exact amount
34 days
Disclosure lag
Traded
Aug 7, 2026
Disclosed
Sep 10, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Jun 11, 2026Federal contract · $100K obligatedDepartment of Veterans Affairs awarded NEOGENOMICS INC: $100K obligated to date
  2. Jun 16, 2026Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations (and 2 more items)
  3. Jun 17, 2026Federal contract · $494K obligatedDepartment of Veterans Affairs awarded NEOGENOMICS INC: $494K obligated to date
  4. Jun 23, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On June 23, 2026, the Board of Directors (the "Board") of NeoGenomics, Inc. (the "Company") increased the size of the Board from nine to ten directors and appointed Carolyn S. Starrett as a director to fill the newly created vacancy, effective immediately.”
  5. Jul 28, 2026Company filing · Form 8-K · ResultsReported its results
  6. Aug 7, 2026 · this disclosureCongressDisclosed purchase of NEO — reported range $1,001 - $15,000

What came next

  1. Aug 7, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On August 11, 2026, NeoGenomics, Inc. (the “Company”) announced that Alicia Olivo, EVP, General Counsel & Business Development, would transition from her role with the Company and cease to serve as General Counsel effective as of September 21, 2026.”
  2. Oct 5, 2026Company filing · Form 8-K · Results, Executive changeChanged a top executive or board member, and reported its results (and 1 more item)“On September 30, 2026, the Board of Directors (the “ Board ”) of the Company approved the appointment of Warren Stone, the Company’s current President and Chief Operating Officer, as Chief Executive Officer of the Company and a member of the Board, effective as of January 4, 2027.”
View the official recordHouse Clerk periodic transaction report

How to read House Clerk periodic transaction report

The STOCK Act is a 2012 US law that requires members of Congress, and some senior staff, to publicly report their stock trades, and those of their spouse and dependent children, within 45 days.

Full guide: What is the STOCK Act?

What else is on file for NeoGenomics Laboratories, Inc.

For NeoGenomics Laboratories, Inc., OQRO holds 1 Congress trade report and 2 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its NEO page.

Other recent filings by Rep. Gilbert Cisneros (CA31)

The full history of Rep. Gilbert Cisneros (CA31) is on the profile page.

How this filing works

Other disclosures at NeoGenomics Laboratories, Inc.

Everything OQRO holds on this company is on its NEO page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data